RGNX 9.63 (+0.73%)
US75901B1070BiotechnologyBiotechnology

Regenxbio (RGNX) Stock Highlights

9.63 | +0.73%
2024-11-21 04:30:50
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

Statistics

Range Today
9.01 9.8
Volume Today 805.7K
Range 1 Year
8.53 28.8
Volume 1 Year 152.5M
Range 3 Year
8.53 36.35
Volume 3 Year 353.58M
Range 10 Year
7.07 85.1
Volume 10 Year 954.31M

Highlights

Market Capitalization 552.92M (small)
Floating Shares 40.89M
Current Price 9.63
Price To Earnings -2.24
Price To Revenue 5.25
Price To Book 1.83
Earnings Per Share -5.01
Payout Ratio 0%

Performance

Latest +0.73%
1 Month -12.37%
3 Months -22.4%
6 Months -40.33%
1 Year -50.99%
3 Years -71.88%
5 Years -74.44%
10 Years -68.18%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.